GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders

BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) — Greater Cannabis Company, Inc. (GCANRx or the Company) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation t…